FCF Biotech Venture Capital Monitor – USA 12/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of December 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 23,607m
  • Compared to December 2022 the financing volume decreased by roughly 26% (31,894m vs. 23,607m)
  •  The top 5 deals exceed USD 273m each, the largest transaction amounted to USD 401m with ElevateBio
  • Bicara Therapeutics has the highest transaction Volume of USD 165m in December, followed by Lyndra Therapeutics USD 123m and Tome Biosciences USD 118m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link.